BiotechTube

BSG005

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Invasive Fungal Infection

Conditions

Invasive Fungal Infection

Trial Timeline

Jul 1, 2024 → Apr 1, 2026

NCT ID
NCT06678113

About BSG005

BSG005 is a phase 1/2 stage product being developed by Alkem Laboratories for Invasive Fungal Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06678113. Target conditions include Invasive Fungal Infection.

What happened to similar drugs?

4 of 20 similar drugs in Invasive Fungal Infection were approved

Approved (4) Terminated (2) Active (15)
🔄Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
🔄Micafungin + fluconazoleAstellas PharmaPhase 3
🔄Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
❌Micafungin + PlaceboAstellas PharmaPhase 3
✅MicafunginAstellas PharmaApproved
🔄Olorofim + AmBisome®ShionogiPhase 3
🔄Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06678113Phase 1/2Recruiting

Competing Products

20 competing products in Invasive Fungal Infection

See all competitors
ProductCompanyStageHype Score
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Trastuzumab deruxtecan + DurvalumabDaiichi SankyoPhase 2
42
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPre-clinical
26
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Pudexacianinium chlorideAstellas PharmaPhase 2
35
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
26
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Isavuconazonium sulfate + Isavuconazonium sulfateAstellas PharmaPhase 2
35
Micafungin + Systemic antifungal therapyAstellas PharmaPhase 2
27
MicafunginAstellas PharmaPre-clinical
26
Micafungin + PlaceboAstellas PharmaPhase 3
32
MicafunginAstellas PharmaApproved
35
Olorofim + AmBisome®ShionogiPhase 3
44
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
44
SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3
47
Herombopag tablets + Herombopag placebo tabletsJiangsu Hengrui MedicinePhase 3
47